Show simple item record

dc.contributor.authorValla, Marit
dc.contributor.authorVatten, Lars Johan
dc.contributor.authorEngstrøm, Monica J
dc.contributor.authorHaugen, Olav Anton
dc.contributor.authorAkslen, Lars A.
dc.contributor.authorBjørngaard, Johan Håkon
dc.contributor.authorHagen, Anne Irene
dc.contributor.authorYtterhus, Borgny
dc.contributor.authorBofin, Anna M.
dc.contributor.authorOpdahl, Signe
dc.date.accessioned2018-06-13T12:28:07Z
dc.date.available2018-06-13T12:28:07Z
dc.date.issued2016-12
dc.identifier.citationValla M, Vatten LJ, Engstrøm MJ, Haugen OA, Akslen LA, Bjørngaard JHB, Hagen AI, Ytterhus B, Bofin A M, Opdahl S. Molecular Subtypes of Breast Cancer: Long-term Incidence Trends and Prognostic Differences. Cancer Epidemiology, Biomarkers and Prevention. 2016;25(12):1625-1634eng
dc.identifier.urihttp://hdl.handle.net/1956/17795
dc.description.abstract<p>Background: Secular trends in incidence and prognosis of molecular breast cancer subtypes are poorly described. We studied long-term trends in a population of Norwegian women born 1886&ndash;1977.</p> <p>Methods: A total of 52,949 women were followed for breast cancer incidence, and 1,423 tumors were reclassified into molecular subtypes using IHC and in situ hybridization. We compared incidence rates among women born 1886&ndash;1928 and 1929&ndash;1977, estimated age-specific incidence rate ratios (IRR), and performed multiple imputations to account for unknown subtype. Prognosis was compared for women diagnosed before 1995 and in 1995 or later, estimating cumulative risk of death and HRs.</p> <p>Results: Between 50 and 69 years of age, incidence rates of Luminal A and Luminal B (HER2&minus;) were higher among women born in 1929 or later, compared with before 1929 [IRRs 50&ndash;54 years; after imputations: 3.5; 95% confidence interval (CI), 1.8&ndash;6.9 and 2.5; 95% CI, 1.2&ndash;5.2, respectively], with no clear differences for other subtypes. Rates of death were lower in women diagnosed in 1995 or later, compared to before 1995, for Luminal A (HR 0.4; 95% CI, 0.3&ndash;0.5), Luminal B (HER2&minus;; HR 0.5; 95% CI, 0.3&ndash;0.7), and Basal phenotype (HR 0.4; 95% CI, 0.2&ndash;0.9).</p> <p>Conclusions: We found a strong secular incidence increase restricted to Luminal A and Luminal B (HER2&minus;) subtypes, combined with a markedly improved prognosis for these subtypes and for the Basal phenotype.</p>eng
dc.language.isoengeng
dc.publisherAmerican Association for Cancer Researcheng
dc.titleMolecular Subtypes of Breast Cancer: Long-term Incidence Trends and Prognostic Differenceseng
dc.typeJournal articleeng
dc.date.updated2018-01-18T11:51:52Z
dc.rights.holderCopyright 2016 American Association for Cancer Researcheng
dc.type.versionacceptedVersioneng
bora.peerreviewedPeer reviewedeng
dc.type.documentJournal article
dc.identifier.cristinID1417483
dc.identifier.doi10.1158/1055-9965.EPI-16-0427eng
dc.source.issn1055-9965eng
dc.source.issn1538-7755eng
dc.relation.journalCancer Epidemiology, Biomarkers and Prevention


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record